| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-02-26 |
| タイトル |
|
|
タイトル |
Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Synovial sarcoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
PARP |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ATR |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
DNA damage |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Honda, Noritaka
Taniguchi, Hirokazu
Ono, Sawana
Hayashi, Fumiko
Imamura, Erika
Gyotoku, Hiroshi
Takemoto Shinnosuke
Takazono, Takahiro
Ishimoto, Hiroshi
Sakamoto, Noriho
Obase, Yasushi
Masutani, Mitsuko
Nishino, Tomoya
Mukae, Hiroshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Synovial sarcoma (SS) is a rare soft tissue sarcoma (STS) with limited treatment options, indicating the need for novel therapeutic strategies. In this study, we investigated the efficacy of talazoparib, a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, and DNA damage response (DDR) inhibitors in SS in vitro. Methods: To investigate the target gene of talazoparib, we examined the mRNA expression of PARP1 and PARP16 in SS, using data from the Gene Expression Omnibus (GEO) database. Cell viability was assessed to evaluate the efficacy and antitumor effects of talazoparib and other drugs in multiple SS cell lines, using MTT assay. Additionally, flow cytometry-based annexin V assay and western blotting were performed to assess cell apoptosis and protein expression levels, respectively. Results: mRNA expression of PARP16 was slightly higher in SS than other STS from GEO profile database. Talazoparib exerts anticancer effects against SS cells with high PARP16 expression by inducing apoptosis and DNA damage, on the other hand, the effects of talazoparib may be limited in SS cells with low PARP16 expression. Treatment with other DDR inhibitors, such as CHK1, WEE1, and ATR, suppressed the proliferation of SS cells. Celarasertib inhibited ATR phosphorylation and induced the cleavage of PARP and γH2AX, suggesting that celarasertib induced DNA damage and cell apoptosis. Combined therapy with talazoparib and ceralasertib exerts antitumor effects against SS cells through DNA damage and apoptosis pathways, suggesting a potential treatment strategy for SS. Conclusion: Talazoparib combined with ATR inhibitor possesses potential application as a therapeutic option for SS. |
|
言語 |
en |
| 書誌情報 |
en : Discover Oncology
巻 17,
号 1,
p. art. no. 279,
発行日 2026-01-15
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2730-6011 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12672-026-04422-5 |
| 権利 |
|
|
権利情報 |
© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Discover Oncology, 17(1), art. no. 279; 2026 |
|
言語 |
en |
DO17_279.pdf (2.4 MB)
